138 results about "Blood flukes" patented technology

A blood fluke infectious oncomelania detection kit and a detection method thereof belongs to the verminosis transmission medium detecting field. The invention provides a kit and a detection method for detecting blood fluke infectious oncomelania based on a loop-mediated isothermal DNA amplification technology (LAMP). According to the LAMP technology principle, six pairs of specific primers for amplifying a DNA fragment between the 20bp and 231bp of the schistosoma japonicum non-long terminal repeated inverse transcription transposon gene (AF412214) are designed. The LAMP method is constructed for detecting blood fluke gene in the body of the infectious oncomelania and the objective for distinguishing the blood fluke infectious oncomelania from the non-infectious oncomelania is reached. Comparing to the conventional blood fluke infectious oncomelania detection method the method of the invention has advantages of easy and fast operation, sensitive and specific without especial equipment and is suitable for bilharziasis controlling personnel use on site.

The invention provides a nano magnetic bead labeled by chicken yolk immune globulin IgY and used for resisting the soluble antigen of schistosoma japonica ovums and a chicken yolk antibody-magnetic bead ELISA (Enzyme-Linked Immuno Sorbent Assay) method for detecting schistosoma japonica circulating antigen. The method comprises the steps of: immunizing a hen with specific antigens of schistosoma japonica with a method of subcutaneous multi-point injection, and extracting, purifying and identifying specific IgY from an egg yolk; and coupling the polyclone IgY on a magnetic bead, and detecting the circulating antigen of the schistosoma by using the magnetic bead-IgY polyclone antibody as a capture antibody and using the specific monoclone IgY antibody as a detecting antibody. The method not only can be used for capturing more antigens by using the magnetic bead and the IgY to increase the sensibility, but also benefits the increase of detecting specificity by using the monoclonal antibody. Thus, the high combination and coordination of sensibility and specificity, required in immunology diagnosis, are realized.

The invention provides a primer group, probe and kit for detection of Schistosoma mansoni. The primer group includes an upstream primer and a downstream primer, wherein the sequence of the upstream primer is shown in SEQ ID No. 1, the sequence of the downstream primer is shown in SEQ ID No. 2. The primer group for detection of Schistosoma mansoni and a probe and kit for detection of Schistosoma mansoniare has simple and convenient operation. It is verified through tests that when the primer group, probe and kit for detection of Schistosoma mansoni are applied to detection of Schistosoma mansoni, high specificity, high sensitivity, high accuracy and good repeatability are achieved, test results can be obtained within 20 minutes, and the primer group, probe and kit have low requirements fortest conditions and technologies of the test staff and low test cost.

The invention discloses a niclosamide controlled-release dispersing agent for killing schistosoma japonicum cercaria and a preparation method thereof. The niclosamide controlled-release dispersing agent for killing the schistosoma japonicum cercaria is characterized in that the compositions of the niclosamide controlled-release dispersing agent are niclosamide, paradichlorobenzene, floating carriers and a dispersing agent and the main compositions of the niclosamide controlled-release dispersing agent are the niclosamide and the paradichlorobenzene, wherein the weight ratio of the niclosamide to the paradichlorobenzene is between 10 and 30 to between 90 and 70. The niclosamide controlled-release dispersing agent and the preparation method have scientific and reasonable formula and ratio, advanced and simple technique and good effect of killing the schistosoma japonicum cercaria. The controlled-release dispersing agent for killing the schistosoma japonicum cercaria, which is prepared by processing the niclosamide, the paradichlorobenzene, corncob particles and so on as materials, is applied to a pathogen generation water area, releases the niclosamide at a fixed quantity in virtue of sublimation of the paradichlorobenzene, freely diffuses in virtue of the molecular tension and the function of the dispersing agent, reaches the predicted concentration in a water body, has long lasting period, effectively kills the schistosoma japonicum cercaria, and prevents the schistosoma japonicum cercaria from infecting human beings and livestock; and the death rate of the schistosoma japonicum cercaria reaches 100 percent.

Schistosoma japonicum egg antigen (SEA) bone marrow dendritic cells produce an exosome, an exosome is obtained by isolating and purifying and is used to treat a mouse with immune diseases, and then various indexes of this mouse such as body weight change, disease activity index, colon length, tissue lesions and pathological tissue score show that the disease of the experimental mouse is clearly better; it is noted that the exosome produced by japonicum egg antigen (SEA) bone marrow dendritic cells (BMDC) has clear therapeutic effect on immune diseases. The invention belongs to biological therapy, toxic and side effects of existing anti-inflammatory drugs are avoided maximally, the exosome has low toxicity and high efficiency, and a new method for treating immune diseases is provided.

The invention relates to the field of genetic engineering antibody, and builds schistosoma japonicum immature egg soluble antigen (SIEA) single-chain antibody library for the first time. By screening the SIEA single-chain antibody library through an immuno-affinity screening technique, a specific single-chain antibody aiming at anti-schistosomiasis-japonica effective natural molecular vaccine SIEA26-28kDa is obtained. The obtainment of the specific single-chain antibody provides a foundation for treating schistosomiasis japonica, utilizing the specific single-chain antibody as a probe to screen schistosoma japonicum cDNA libraries and obtaining a corresponding gene sequence aiming at anti-schistosomiasis-japonica effective vaccine molecules more conveniently and rapidly.

The invention discloses a single-chain antibody of an anti-schistosome monoclonal NP11-4 as well as a preparation method and application thereof, and relates to the field of gene engineering and the field of therapeutic drugs against schistosomiasis. The invention is to use a monoclonal antibody NP11-4 located at adult membrane, cercaria memberane, schistosomulum membrane, egg shell and miracidium in egg of Schistosoma japonicum, extract total RNA of hybridoma cells through a gene engineering technology, adopt RT-PCR for proliferation of genes VH and VL, and use overlap-extension PCR to connect the genes VH and VL into a single-chain antibody gene in the form of VH<-linker-VL, which is subsequently connected with a pBAD / gIIIA carrier and cloned into Top10F'of Escherichia Coli to induce a soluble expression of the target gene. The zone from amino acid No.1 to No. 122 of the expressed single-chain antibody of the anti-schistosome monoclonal NP11-4 is a heavy chain gene repertoire of the single-chain antibody (VH), and the zone from the amino acid No.141 to No.254 is a light chain gene repertoire (VL) of the single-chain antibody, wherein the linker between the heavy and light chain gene repertoires consists of 18 amino acids including repeated glycines and serines, and the single-chain antibody has 254 amino acids in full length.

The invention provides a water surface floatation sustained release medicament for prevention and cure of schistosomiasis, which is a granular sustained release medicament prepared from medicinal active constituent 5.0-60 wt%, solid state carrier material 30.0-90.0wt%, dispersing agent 0.1-10.0 wt%, coating agent 2.0-10.0 wt%, and hydrophobing agent 0.1-5.0 wt%.

The Japanese blood fluke nucleic acid vaccine consists of eukaryotic expression vector pCD or pBK and blood fluke antigen genes. The blood fluke antigen genes includes Japanese blood fluke antigen genes Sj-23, Sj-26 and Sj-32 and constitute monovalent nucleic acid vaccines pCD-Sj23, pCD-Sj26, pCD-Sj32 and pBK-Sj26 and multivalent nucleic acid vaccine pBK-Sj26-Sj23. The vaccines have blood fluke reducing rate of 35.4-44.4 % and blood fluke egg reducing rate in liver of 39.6-69.0 %, and can induce effectively the immunological protecting capacity to blood fluke. Once immunization has relatively long immunological effect, and the present invention has no environmental pollution, bad influence, and bad reaction.